| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 38, 658-662, Copyright © 1992 by American Association for Clinical Chemistry
JJ Albers, SM Marcovina and H Kennedy
Department of Medicine, University of Washington, Seattle 98103.
The first phase of an international collaborative study for standardization of test systems for measuring apolipoprotein (apo) A-I and apo B demonstrated that uniformity of apo A-I and apo B measurements can be achieved if suitable common reference materials are used to calibrate the different systems. The objective of the second phase was to evaluate the linearity and parallelism or proportionality of the candidate reference materials selected in phase one and to determine whether any of them could be proposed as international reference materials. We evaluated the proposed reference materials with 37 test systems for apo A-I and 38 for apo B, involving 23 manufacturers and five research laboratories. Two lyophilized preparations were proposed for apo A-I, SP1 from Behringwerke AG and SP2 from Daiichi Pure Chemicals Co., and two liquid preparations were proposed for apo B, SP3 from Behringwerke AG and SP4 from Reagents Applications. The linearity of the candidate reference materials was compared with the linearity of a frozen serum pool or interim serum reference material distributed to all the participants and with that of a fresh serum pool prepared by each participant. SP1 and SP3 exhibited linearity and parallelism similar to that of the fresh frozen serum pool and had among-laboratory CVs less than or similar to those obtained on normolipidemic serum samples (approximately 6% for apo A-I and approximately 7% for apo B).
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  J. J.P. Kastelein, W. A. van der Steeg, I. Holme, M. Gaffney, N. B. Cater, P. Barter, P. Deedwania, A. G. Olsson, S. M. Boekholdt, D. A. Demicco, et al. Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment Circulation, June 10, 2008; 117(23): 3002 - 3009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Baca and G. R. Warnick Estimation of LDL-Associated Apolipoprotein B from Measurements of Triglycerides and Total Apolipoprotein B Clin. Chem., May 1, 2008; 54(5): 907 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. van der Steeg, I. Holme, S. M. Boekholdt, M. L. Larsen, C. Lindahl, E. S.G. Stroes, M. J. Tikkanen, N. J. Wareham, O. Faergeman, A. G. Olsson, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 634 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Arsenault, I. Lemieux, J.-P. Despres, N. J. Wareham, R. Luben, J. J.P. Kastelein, K.-T. Khaw, and S. M. Boekholdt Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study Eur. Heart J., November 2, 2007; 28(22): 2770 - 2777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Birjmohun, G. M. Dallinga-Thie, J. A. Kuivenhoven, E. S.G. Stroes, J. D. Otvos, N. J. Wareham, R. Luben, J. J.P. Kastelein, K.-T. Khaw, and S. M. Boekholdt Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease Circulation, October 30, 2007; 116(18): 2029 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. van der Steeg, S. M. Boekholdt, E. A. Stein, K. El-Harchaoui, E. S.G. Stroes, M. S. Sandhu, N. J. Wareham, J. W. Jukema, R. Luben, A. H. Zwinderman, et al. Role of the Apolipoprotein B-Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case-Control Analysis in EPIC-Norfolk Ann Intern Med, May 1, 2007; 146(9): 640 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T.P. Keulen, M. Kruijshoop, N. C. Schaper, A. P.G. Hoeks, and T. W.A. de Bruin Increased Intima-Media Thickness in Familial Combined Hyperlipidemia Associated With Apolipoprotein B Arterioscler. Thromb. Vasc. Biol., February 1, 2002; 22(2): 283 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Frohlich, A. Sniderman, and R. H. Eckel Familial Combined Hyperlipidemia and Insulin Resistance Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 2100 - 2101. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Sniderman, T. Scantlebury, and K. Cianflone Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus Ann Intern Med, September 18, 2001; 135(6): 447 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Porsch-Ozcurumez, S. Westphal, and C. Luley Measurement of Low Apolipoprotein Concentrations by Optimized Immunoturbidimetric Applications Clin. Chem., March 1, 2001; 47(3): 594 - 597. [Full Text] [PDF]
|
|
|
|
|
|
S. S. Gidding, L. C. Bookstein, and E. V. Chomka Usefulness of Electron Beam Tomography in Adolescents and Young Adults With Heterozygous Familial Hypercholesterolemia Circulation, December 8, 1998; 98(23): 2580 - 2583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Brown, R. G. Bakker-Arkema, L. Yellen, R. W. Henley Jr., R. Guthrie, C. F. Campbell, M. Koren, W. Woo, R. McLain, and D. M. Black Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin J. Am. Coll. Cardiol., September 1, 1998; 32(3): 665 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Jungner, S. M. Marcovina, G. Walldius, I. Holme, W. Kolar, and E. Steiner Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization–International Federation of Clinical Chemistry First International Reference Materials Clin. Chem., August 1, 1998; 44(8): 1641 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Graziani, L. Zanolla, G. Righetti, C. Marchetti, P. Mocarelli, and S. M. Marcovina Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group Clin. Chem., January 1, 1998; 44(1): 134 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Sniderman Counterpoint To (measure apo)B or not to (measure apo)B: a critique of modern medical decision-making Clin. Chem., August 1, 1997; 43(8): 1310 - 1314. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. Stein, D. Sprecher, K.S. Allenby, R.L. Tosiello, E. Whalen, and S.R. Ripa Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(1): 7 - 16. [Abstract] [PDF]
|
|
|
|
|
|
J. L. Isaacsohn, R. G. Bakker-Arkema, R. Fayyad, R. Whitcomb, and D. M. Black Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients with Hypercholesterolemia Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 243 - 249. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
